Literature DB >> 17039230

Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.

A Fiorini, G Reddiconto, G Farina, S Marietti, M Palladino, P Chiusolo, G Leone, S Sica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17039230     DOI： 10.1038/sj.leu.2404430

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.

Authors:  Constantine S Tam; Roberto M Nussenzveig; Uday Popat; Carlos E Bueso-Ramos; Deborah A Thomas; Jorge A Cortes; Richard E Champlin; Stefan E Ciurea; Taghi Manshouri; Sherry M Pierce; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

2.  Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Authors:  David S Snyder; Joycelynne Palmer; Karl Gaal; Anthony S Stein; Vinod Pullarkat; Firoozeh Sahebi; Nyana Vora; Ryotaro Nakamura; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

3.  JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.

Authors:  Thoralf Lange; Anja Edelmann; Udo Siebolts; Rainer Krahl; Claudia Nehring; Nadja Jäkel; Michael Cross; Jacqueline Maier; Dietger Niederwieser; Claudia Wickenhauser
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.